📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Imugene Ltd (IMU)

Sydney
Currency in AUD
Disclaimer
0.048
-0.001(0.00%)
Closed
IMU Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.0480.049
52 wk Range
0.0390.150
Bid/Ask
0.048 / 0.049
Prev. Close
0.049
Open
0.049
Day's Range
0.048-0.049
52 wk Range
0.039-0.15
Volume
8,751,207
Average Volume (3m)
20,284,639
1-Year Change
8.89%
Fair Value
Unlock
Fair Value Upside
Unlock
IMU Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
0.337
Upside
+602.083%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Imugene Ltd Company Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Compare IMU to Peers and Sector

Metrics to compare
IMU
Peers
Sector
Relationship
P/E Ratio
−2.4x−4.7x−0.6x
PEG Ratio
0.01−0.050.00
Price/Book
3.1x3.6x2.6x
Price / LTM Sales
73.3x12.8x3.3x
Upside (Analyst Target)
-201.6%44.5%
Fair Value Upside
Unlock−7.3%6.0%Unlock

FAQ

What Is the Imugene Ltd (IMU) Stock Price Today?

The Imugene Ltd stock price today is 0.048

What Stock Exchange Does Imugene Ltd Trade On?

Imugene Ltd is listed and trades on the Sydney stock exchange.

What Is the Stock Symbol for Imugene Ltd?

The stock symbol for Imugene Ltd is "IMU."

What Is the Imugene Ltd Market Cap?

As of today, Imugene Ltd market cap is 364.43M.

What is Imugene Ltd Earnings Per Share?

The Imugene Ltd EPS is -0.021.

What Is the Next Imugene Ltd Earnings Date?

Imugene Ltd will release its next earnings report on 26 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.